Hemostemix's Expands its Marketing Team Focused on Sales in Florida

Core Insights - Hemostemix Inc. has expanded its marketing team to enhance sales efforts in Florida, focusing on the promotion of its VesCell™ therapy for various cardiovascular and podiatric conditions [1][2][6] Company Developments - The newly appointed commercial team includes experienced professionals with a strong background in the biopharmaceutical industry, aimed at effectively marketing VesCell™ to healthcare providers [2][4] - Croom Lawrence, the Chief Commercial Officer, has over 25 years of experience in biotech commercial launches, having supported over 15 blockbuster launches and generating significant returns on marketing investments for major biotech firms [4] - Sana Farooqui, the Fractional Chief Marketing Officer, will lead digital and social marketing efforts, ensuring compliance and impactful messaging [4] - Bob Branch, the Fractional Vice President of Digital Marketing & Media, brings over 20 years of experience in medical marketing, focusing on omnichannel strategies [4] Product Efficacy - VesCell™ has shown promising results in clinical trials, including improved limb circulation and reduced amputation rates for patients with Peripheral Arterial Disease (PAD) and Chronic Limb-Threatening Ischemia (CLTI) [5] - In studies involving cardiology patients, VesCell™ has demonstrated increased ejection fraction, reduced severe angina, and improved quality of life [5] - Early results suggest potential cognitive benefits in vascular dementia patients treated with VesCell™ [5] Regulatory Context - Under Florida's Right-to-Try statute, eligible physicians can offer VesCell™ to patients suffering from severe conditions, following informed consent [2][6] - Hemostemix has completed seven clinical studies involving 318 subjects, with results published in 11 peer-reviewed articles, establishing the safety and efficacy of VesCell™ [7]